Alcon (ALC) Reports Q4 Earnings: What Key Metrics Have to Say
- While the top- and bottom-line numbers for Alcon (ALC) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 02/25/2025
|
Alcon Reports Full-Year 2024 Results, with Strong Top-line and Earnings Growth and Record Cash Generation
- GENEVA--(BUSINESS WIRE)--Alcon Reports Full-Year 2024 Results, with Strong Top-line and Earnings Growth and Record Cash Generation.
- 02/25/2025
|
Alcon Announces U.S. Launch of New SYSTANE PRO Preservative-Free, Revolutionizing Dry Eye Relief With Its Longest Lasting Formula Yet
- GENEVA--(BUSINESS WIRE)--Alcon Announces U.S. Launch of New SYSTANE PRO Preservative-Free, Revolutionizing Dry Eye Relief with Its Longest Lasting Formula Yet.
- 02/24/2025
|
Wall Street's Insights Into Key Metrics Ahead of Alcon (ALC) Q4 Earnings
- Evaluate the expected performance of Alcon (ALC) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
- 02/20/2025
|
Alcon Announces U.S. Launch of Voyager DSLT, First-of-its-Kind Treatment for Glaucoma and Ocular Hypertension
- GENEVA--(BUSINESS WIRE)--Alcon Announces U.S. Launch of Voyager DSLT, First-of-its-Kind Treatment for Glaucoma and Ocular Hypertension.
- 02/19/2025
|
Algoma Central Corporation Announces a 5% Increase in Quarterly Dividend
- ST. CATHARINES, Ontario--(BUSINESS WIRE)-- #yourmarinecarrierofchoice--Algoma Central Corporation (“Algoma” or “the Company”) (TSX: ALC), a leading provider of marine transportation services, today announced that the Company's Board of Directors authorized payment of a quarterly dividend to shareholders of $0.20 per common share. The dividend is payable on March 3, 2025 to shareholders of record on February 14, 2025. This $0.20 common share dividend represents a 5% increase from the $0.19 per share dividend paid on Decembe.
- 01/17/2025
|
Alcon to Present at 2025 Annual J.P. Morgan Healthcare Conference
- GENEVA--(BUSINESS WIRE)--Alcon to Present at 2025 Annual J.P. Morgan Healthcare Conference.
- 12/31/2024
|
Here's Why Alcon (ALC) is a Strong Growth Stock
- Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- 12/23/2024
|
RxSight downgraded to Hold from Buy at Stifel
- Stifel downgraded RxSight (RXST) to Hold from Buy with a price target of $40, down from $65. The firm's latest deep-dive survey of surgeons leads to believe that the risk from U.S. premium IOL - intraocular lens - competition may be more material than investors appreciate, with JNJ's (JNJ) new Tecnis Odyssey lens "jumping off the page" in its findings and with Alcon's (ALC) PanOptix Pro around the corner, the analyst tells investors in a research note. Stifel adds that its longitudinal analysis shows the respondents' 2025 LAL - light adjustable lenses - volume expectations are moderately weakening, giving the firm pause around the intermediate-term LAL path ahead. RxSight +1.02 (+2.74%) Johnson & Johnson -1.16 (-0.80%) Alcon -0.56 (-0.66%)
- 12/19/2024
|
Needham ups Alcon target, adds to Conviction List
- Needham earlier today raised the firm's price target on Alcon (ALC) to $108 from $103 and kept a Buy rating on the shares. The firm also added the stock to its Conviction List, replacing RxSight (RXST). Alcon's product launch lineup is one of the best it's been since its spin from Novartis, the analyst told investors in a research note. Needham expects the product launches to result in Alcon's revenue growth accelerating throughout 2025, which should drive multiple expansion. The firm made the stock a top pick for 2025. With the stock's valuation meaningfully below Alcon's historical range, risks around currency and commercial investments are baked in, making the risk/reward attractive, contended Needham. Alcon +1.88 (+2.24%) RxSight -0.1 (-0.26%)
- 12/17/2024
|
Reasons to Retain Alcon Stock in Your Portfolio for Now
- Strong growth in the Surgical and Vision Care businesses raises investors' optimism for ALC.
- 12/13/2024
|
Why Alcon (ALC) is a Top Growth Stock for the Long-Term
- Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- 12/06/2024
|
Alcon (ALC) is a Top-Ranked Value Stock: Should You Buy?
- The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
- 11/18/2024
|
Alcon: Q3, Slight Guidance Cut Is Not Something Structural
- I reiterate a 'Strong Buy' rating for Alcon with a one-year price target of $118 per share, despite a minor guidance cut. Alcon's new product launches, including PRECISION7 and Systane Pro, are expected to drive significant growth in the vision segment. Alcon's surgical business, with a strong position in cataract surgery, is projected to grow 7% annually, driven by advanced technology and international expansion.
- 11/14/2024
|
Alcon (ALC) Q3 2024 Earnings Call Transcript
- Alcon Inc. (NYSE:ALC ) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ET Company Participants David Endicott - Chief Executive Officer Tim Stonesifer - Chief Financial Officer Dan Cravens - Vice President, Investor Relations Conference Call Participants Graham Doyle - UBS Jack Reynolds-Clark - RBC Capital Markets David Saxon - Needham & Co. Larry Biegelsen - Wells Fargo Patrick Wood - Morgan Stanley Ryan Zimmerman - BTIG Jeff Johnson - Baird Anthony Petrone - Mizuho Tom Stephan - Stifel Brett Fishbin - Keybanc Capital Markets David Adlington - JP Morgan Giang Nguyen - Citi Issie Kirby - Redburn Atlantic Sajid Aznar - HSBC Falco Freidrichs - Deutsche Bank Operator Greetings and welcome to the Alcon third quarter 2024 earnings conference call. At this time, all participants are in a listen-only mode.
- 11/13/2024
|
Alcon Q3 Earnings Top Estimates, Margins Up, Stock Gains in Afterhours
- ALC's performance is driven by robust demand for the company's innovative products, balanced geographic footprint and strong execution by the team.
- 11/13/2024
|
Alcon cuts 2024 forecasts, as slow US hits surgical unit
- Eye-care group Alcon cut its 2024 forecasts and missed market expectations for third-quarter sales on Tuesday evening, as a soft U.S. market hit its surgical business.
- 11/13/2024
|
Alcon (ALC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
- While the top- and bottom-line numbers for Alcon (ALC) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 11/12/2024
|
Alcon Reports Solid Third-Quarter 2024 Results, including Double-Digit Earnings Growth and Record Cash Generation
- GENEVA--(BUSINESS WIRE)--Alcon Reports Solid Third-Quarter 2024 Results, including Double-Digit Earnings Growth and Record Cash Generation.
- 11/12/2024
|
What Analyst Projections for Key Metrics Reveal About Alcon (ALC) Q3 Earnings
- Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Alcon (ALC), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.
- 11/07/2024
|
Algoma Central Corporation to Issue Third Quarter Financial Results on November 4, 2024
- ST. CATHARINES, Ontario--(BUSINESS WIRE)-- #yourmarinecarrierofchoice--Algoma Central Corporation (TSX: ALC) today announced it will report its financial results for the three and nine months ended September 30, 2024 before market open on November 4, 2024. The Company's third quarter earnings release and full financial results will be available on the Company's website and on SEDAR. Algoma Central Corporation is a global provider of marine transportation that owns and operates dry and liquid bulk carriers, serving markets.
- 10/21/2024
|
Reasons to Retain Alcon Stock in Your Portfolio for Now
- Strong growth in the Surgical and Vision Care businesses raises investors' optimism for ALC.
- 09/24/2024
|
Innovation Aids Alcon Stock's Growth Despite Macroeconomic Troubles
- Banking on strong sales of its contact lenses and ocular health products, ALC is registering solid growth within Vision Care.
- 09/20/2024
|
Bausch Reportedly Explores A Sale; Could Alcon, J&J Or AbbVie Buy It?
- Bausch + Lomb stock surged Monday — briefly breaking out — on a report the company is working with advisors to explore a potential sale.
- 09/16/2024
|
Alcon Analysts Increase Their Forecasts After Q2 Results
- Alcon Inc. ALC reported mixed second-quarter results, after the closing bell on Tuesday.
- 08/22/2024
|
Alcon CEO: 'Very good' revenue and underlying demand in Q2
- Alcon CEO David Endicott comments on the company's second-quarter results.
- 08/22/2024
|
Alcon Inc. (ALC) Q2 2024 Earnings Call Transcript
- Alcon Inc. (NYSE:ALC ) Q2 2024 Earnings Conference Call August 21, 2024 8:00 AM ET Company Participants Dan Cravens - Vice President, Investor Relations David Endicott - Chief Executive Officer Tim Stonesifer - Chief Financial Officer Conference Call Participants Jeff Johnson - Baird Graham Doyle - UBS Veronika Dubajova - Citi Ryan Zimmerman - BTIG David Adlington - JPMorgan Patrick Wood - Morgan Stanley Jack Reynolds-Clark - RBC Capital Markets David Saxon - Needham & Company Anthony Petrone - Mizuho Group Larry Biegelsen - Wells Fargo Michael Sarcone - Jefferies Issie Kirby - Redburn Atlantic Richard Felton - Goldman Sachs Tom Stephan - Stifel Steven Lichtman - Oppenheimer & Company Brett Fishbin - KeyBanc Capital Markets Operator Greetings and welcome to the Alcon Second Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode.
- 08/21/2024
|
Alcon (ALC) Q2 Earnings Meet Estimates, Revenues Increase Y/Y
- Alcon (ALC) delivers impressive growth in Implantables and Contact Lenses in the second quarter of 2024.
- 08/21/2024
|
Alcon (ALC) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
- The headline numbers for Alcon (ALC) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 08/20/2024
|
Alcon Reports Second-Quarter 2024 Results with Strong Growth in Implantables and Contact Lenses
- GENEVA--(BUSINESS WIRE)--Alcon Reports Second-Quarter 2024 Results with Strong Growth in Implantables and Contact Lenses.
- 08/20/2024
|
Alcon's (ALC) Market Share Gains, New Launches Aid Growth
- Alcon (ALC) is witnessing growth in its over-the-counter portfolio, driven by favorable pricing and a sustained family of products.
- 08/20/2024
|
Countdown to Alcon (ALC) Q2 Earnings: Wall Street Forecasts for Key Metrics
- Get a deeper insight into the potential performance of Alcon (ALC) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
- 08/15/2024
|
Is Alcon (ALC) Outperforming Other Medical Stocks This Year?
- Here is how Alcon (ALC) and Addex Therapeutics Ltd. Sponsored ADR (ADXN) have performed compared to their sector so far this year.
- 08/05/2024
|
Air Lease Corporation Announces Delivery of First of 19 New Airbus Aircraft to Condor, Germany
- LOS ANGELES--(BUSINESS WIRE)--Today Air Lease Corporation (NYSE: AL) announced the delivery of one new Airbus A321-200neo to Condor. This aircraft is the first of 19 new Airbus aircraft confirmed to deliver to the airline from ALC's orderbook with Airbus through 2027, including 17 A321-200neos and two A320-200neos. In addition to these aircraft, ALC currently has three A321s and two A320s on long-term lease to the airline. “ALC is pleased to announce this significant first of 19 new Airbus airc.
- 07/18/2024
|
Here's Why Alcon (ALC) is a Strong Momentum Stock
- The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
- 07/17/2024
|
The Zacks Analyst Blog DexCom, Hologic, Alcon Intuitive Surgical and Thermo Fisher Scientific
- DexCom, Hologic, Alcon Intuitive Surgical and Thermo Fisher Scientific are included in this Analyst Blog.
- 07/16/2024
|
Alcon (ALC) Rides on Innovation, Balanced Segmental Sales
- Alcon (ALC) is witnessing growth in its over-the-counter portfolio, mainly driven by favorable pricing and a sustained family of products.
- 07/15/2024
|
Buy 5 Medical Devices Stocks to Enhance Your Portfolio in 2H
- We have narrowed our search to five Medical Instruments stocks. These are: DXCM, TMO, ISRG, ALC, HOLX.
- 07/15/2024
|
Alcon (ALC) Inks Buyout Deal to Expand Its Glaucoma Portfolio
- Alcon (ALC) announces the closing of its deal to acquire BELKIN Vision. Per the terms of the agreement, Alcon will have access to BELKIN Vision's Direct Selective Laser Trabeculoplasty technology.
- 07/05/2024
|
Alcon (ALC) Achieves FDA 510(k) Clearance for Unity VCS and Unity CS
- Alcon (ALC) gets FDA 510(k) clearance for its Unity VCS and Unity CS. The company will start a thorough program to get real-world feedback before the systems' commercial launch in 2025.
- 06/24/2024
|
Alcon's Latest Equipment Breakthrough Technologies, Unity VCS and Unity CS, Receive U.S. FDA 510(k) Clearance
- GENEVA--(BUSINESS WIRE)--Alcon's Latest Equipment Breakthrough Technologies, Unity VCS and Unity CS, Receive U.S. FDA 510(k) Clearance.
- 06/24/2024
|
Why Alcon (ALC) is a Top Momentum Stock for the Long-Term
- Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
- 06/10/2024
|
Reasons to Include Alcon (ALC) in Your Portfolio Right Now
- New product launches and strong solvency bode well for Alcon (ALC).
- 05/24/2024
|
Is Alcon (ALC) Stock Outpacing Its Medical Peers This Year?
- Here is how Alcon (ALC) and CalciMedica Inc. (CALC) have performed compared to their sector so far this year.
- 05/23/2024
|
Buy 5 Medical Instruments Stocks to Enhance Your Portfolio
- We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These stocks are: ALC, RXST, HOLX, VCYT, MASI.
- 05/23/2024
|
Algoma Central Corporation Announces Convertible Debenture Conversion Price
- ST. CATHARINES, Ontario--(BUSINESS WIRE)-- #yourmarinecarrierofchoice--Algoma Central Corporation (TSX: ALC) (TSX: ALC.DB.A) announced today that following the second quarter dividend of $0.19 per common share, an adjustment has been made to the conversion price of the convertible debentures, reducing it to $14.10. The convertible debentures have a maturity date of June 30, 2024. The second quarter dividend will be paid on June 3, 2024 to shareholders of record on May 17, 2024. About Algoma Central Corporation Algoma Centr.
- 05/23/2024
|
3 Solid Buys From MedTech Following 2024 Guidance Raise
- Guidance hikes by BSX, ALGN and ALC for 2024 make them attractive investment bets.
- 05/15/2024
|
Alcon (ALC) Q1 Earnings Surpass Estimates, Margins Expand
- Alcon's (ALC) Q1 results reflect substantial growth in its franchises on the back of healthy markets.
- 05/14/2024
|
Alcon Inc. (ALC) Q1 2024 Earnings Call Transcript
- Alcon Inc. (NYSE:ALC ) Q1 2024 Earnings Conference Call May 14, 2024 8:00 AM ET Company Participants Dan Cravens - Vice President, Investor Relations David Endicott - Chief Executive Officer Tim Stonesifer - Chief Financial Officer Conference Call Participants Graham Doyle - UBS Veronica Dubajova - Citi Ryan Zimmerman - BTIG Richard Felton - Goldman Sachs Larry Biegelsen - Wells Fargo Jack Reynolds-Clark - RBC Capital Markets David Saxon - Needham & Co Michael Sarcone - Jefferies Brett Fishbin - KeyBanc Capital Markets Anthony Petrone - Mizuho Group Issie Kirby - Redburn Atlantic Tom Stephan - Stifel Operator Greetings, and welcome to the Alcon's First Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode.
- 05/14/2024
|
Compared to Estimates, Alcon (ALC) Q1 Earnings: A Look at Key Metrics
- Although the revenue and EPS for Alcon (ALC) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 05/13/2024
|
2 Intriguing Medical Stocks to Buy for Steady Growth as Earnings Approach
- Among the medical sector, Alcon (ALC) and Prestige Consumer Healthcare (PBH) are two intriguing stocks to buy for growth as their quarterly results approach on Tuesday, May 14.
- 05/13/2024
|
Alcon Reports Strong First-Quarter 2024 Results Driven by Robust Sales in Contact Lenses and Ocular Health
- GENEVA--(BUSINESS WIRE)--Alcon Reports Strong First-Quarter 2024 Results Driven by Robust Sales in Contact Lenses and Ocular Health.
- 05/13/2024
|
Why Alcon (ALC) Might Surprise This Earnings Season
- Alcon (ALC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 05/10/2024
|
ALC vs. EW: Which Stock Is the Better Value Option?
- Investors interested in stocks from the Medical - Instruments sector have probably already heard of Alcon (ALC) and Edwards Lifesciences (EW). But which of these two stocks presents investors with the better value opportunity right now?
- 05/07/2024
|
Star Surgical Shines as U.S. Outlook Improves for 2024
- STAAR Surgical Co. NASDAQ: STAA develops and manufactures intraocular lenses (IOL) used to replace a person's natural lenses during cataract surgery. Its portfolio includes the EVO line of Implantable Collamer Lenses (ICL) used for the treatment of nearsightedness (myopia), refractive error (astigmatism) and farsightedness (presbyopia).
- 04/16/2024
|
Alcon Publishes Agenda for 2024 Annual General Meeting
- GENEVA--(BUSINESS WIRE)--Alcon Publishes Agenda for 2024 Annual General Meeting.
- 04/07/2024
|
Here's Why Investors Should Buy Alcon (ALC) Stock Right Now
- Strength in the Surgical and Vision Care businesses bodes well for Alcon (ALC).
- 04/03/2024
|
Alcon's (ALC) New Launch Strengthens IOL Innovation Leadership
- Alcon's (ALC) Clareon platform is available in India in two PCIOL technologies, PanOptix and Vivity.
- 03/13/2024
|
Alcon Strengthens Leadership in IOL Innovation with the launch of the Clareon Presbyopia Correcting IOLs in India
- Clareon PCIOLs deliver excellent vision, exceptional clarity and predictable refractive outcomes in a glistening-free§ IOL material12-14 Clareon IOLs offer long-lasting clarity backed by extensive real-world experience with excellent outcomes, which is demonstrated in 30 peer-reviewed studies15-17 BENGALURU, India–(BUSINESS WIRE)–Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced …
- 03/12/2024
|
Alcon's (ALC) Vivity EDOF IOL Achieves One Million Milestone
- Alcon's (ALC) Vivity features the first-of-its-kind, patented wavefront-shaping technology, which simplifies presbyopia correction for surgeons and patients.
- 03/08/2024
|
Vivity, the World's Leading EDOF IOL, Reaches One Million Milestone
- TORONTO--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today proudly announces AcrySof® IQ Vivity® and Clareon® Vivity extended depth of focus (EDOF) intraocular lens (IOL) has surpassed more than one million implants worldwide. Vivity is the most implanted EDOF IOL globally.1* Alcon is the global leader in IOLs—every four seconds an eye is implanted with an Alcon IOL—and continues to innovate in this space to address patients.
- 03/06/2024
|
Alcon, Inc. (ALC) Q4 2023 Earnings Call Transcript
- Alcon, Inc. (ALC) Q4 2023 Earnings Call Transcript
- 02/28/2024
|
Alcon (ALC) Q4 Earnings Beat Estimates, Margins Expand
- Alcon (ALC) delivers impressive performance across its franchises in the fourth quarter of 2023.
- 02/28/2024
|
Alcon (ALC) Reports Q4 Earnings: What Key Metrics Have to Say
- Although the revenue and EPS for Alcon (ALC) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 02/27/2024
|
Alcon's Broad Portfolio Delivers Robust Sales and Earnings Growth in FY 2023
- GENEVA--(BUSINESS WIRE)--Alcon's Broad Portfolio Delivers Robust Sales and Earnings Growth in FY 2023.
- 02/27/2024
|
Alcon (ALC) Faces Rising Expenses, Tough Competitive Scenario
- In the surgical business, Alcon (ALC) faces a mix of competitors, ranging from large manufacturers with multiple business lines to small manufacturers.
- 02/27/2024
|
Wall Street's Insights Into Key Metrics Ahead of Alcon (ALC) Q4 Earnings
- Beyond analysts' top -and-bottom-line estimates for Alcon (ALC), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.
- 02/22/2024
|
Alcon (ALC) Business Hurt by Macroeconomic Woes, Competition
- In the surgical business, Alcon (ALC) faces a mix of competitors, ranging from large manufacturers with multiple business lines to small manufacturers.
- 01/04/2024
|
ALC or IDXX: Which Is the Better Value Stock Right Now?
- Investors with an interest in Medical - Instruments stocks have likely encountered both Alcon (ALC) and Idexx Laboratories (IDXX). But which of these two stocks presents investors with the better value opportunity right now?
- 11/16/2023
|
Alcon (ALC) Q3 Earnings Miss Estimates, Margins Increase
- Alcon (ALC) Q3 revenues increase year over year, driven by strength in Surgical and Vision Care segments.
- 11/15/2023
|
Alcon (ALC) Reports Q3 Earnings: What Key Metrics Have to Say
- While the top- and bottom-line numbers for Alcon (ALC) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 11/15/2023
|
Alcon's stock falls as third-quarter sales miss estimates
- Alcon Inc. shares ALC, +4.04% dropped more than 4% premarket on Wednesday after the eye care company on Tuesday reported third-quarter revenues below analysts' expectations.
- 11/15/2023
|
Here's Why Investors Should Buy Alcon (ALC) Stock Right Now
- Investors continue to be optimistic about Alcon (ALC), backed by a competitive product portfolio and strong commercial execution.
- 11/14/2023
|
Is Alcon (ALC) Stock Outpacing Its Medical Peers This Year?
- Here is how Alcon (ALC) and Alpine Immune Sciences, Inc. (ALPN) have performed compared to their sector so far this year.
- 11/13/2023
|
Are Medical Stocks Lagging Alcon (ALC) This Year?
- Here is how Alcon (ALC) and Alpine Immune Sciences, Inc. (ALPN) have performed compared to their sector so far this year.
- 10/27/2023
|
Alcon (ALC) Stock Up 9.7% YTD: Will the Rally Continue?
- Alcon (ALC) continues gaining from the company's diverse portfolio, incremental innovation, and new product launches.
- 10/16/2023
|
Alcon (ALC) Gains From Growing Market Demand, New Launches
- Within Vision Care, Alcon (ALC) is registering solid growth, banking on strong sales of its contact lenses and ocular health products.
- 10/12/2023
|
Is Alcon (ALC) Stock Outpacing Its Medical Peers This Year?
- Here is how Alcon (ALC) and Cardinal Health (CAH) have performed compared to their sector so far this year.
- 10/11/2023
|
Alcon (ALC) Loses -6.61% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
- Alcon (ALC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- 10/02/2023
|
Protect Your Portfolio From Volatility With 3 Low-Beta Picks
- At this stage, it is prudent to invest in low-beta stocks with a favorable Zacks Rank like ALC, RDY and ANIK, as these will be less volatile than the broader market.
- 09/29/2023
|
Is Alcon (ALC) Outperforming Other Medical Stocks This Year?
- Here is how Alcon (ALC) and Molina (MOH) have performed compared to their sector so far this year.
- 09/25/2023
|
Here's Why Investors Should Buy Alcon (ALC) Stock Right Now
- Investors continue to be optimistic about Alcon (ALC) on the impressive performance of its portfolio.
- 09/21/2023
|
Alcon (ALC) Gains From Innovation & International Expansion
- Alcon's (ALC) Surgical business continues to gain from diverse portfolio and incremental innovation.
- 09/15/2023
|
Alcon (ALC) Surgical Advances With New Data on AcrySof IQ Vivity
- Alcon's (ALC) Vivity Registry study data highlights the lens's versatility in treating a wide range of patients.
- 09/11/2023
|
3 MedTech Stocks to Bet on Potential Pause of Rate Hike by Fed
- Interest rates impact the healthcare industry and medical device companies in various ways. Here we discuss three companies HCA, ALC and SEM that are likely to gain potential pause in rate hikes.
- 09/01/2023
|
Has Alcon (ALC) Outpaced Other Medical Stocks This Year?
- Here is how Alcon (ALC) and RxSight, Inc. (RXST) have performed compared to their sector so far this year.
- 08/22/2023
|
Alcon (ALC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
- While the top- and bottom-line numbers for Alcon (ALC) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 08/15/2023
|
Time to Buy These Medical Stocks as Earnings Approach
- Quarterly results from large retailers will highlight this week's earnings lineup but there are a few healthcare companies that investors will want to pay attention to as well.
- 08/14/2023
|
Alcon: Lackluster Growth Given Its Valuation
- Alcon stock is currently trading at over 30x earnings, which is considered high for a company not expected to deliver EPS above 20 - 25% in the next few years. Despite the high trading multiple, Alcon has a strong business model and is a leader in the eye care industry, with recent positive developments in its product line and services. Alcon's share price is currently inflated due to hopes of significant free cash flow being diverted to shareholders, but I suggest this optimism may be misplaced and recommend a hold rating for the company.
- 07/26/2023
|
3 Medical Instruments Stocks to Buy Amid Improving Industry Trends
- A financial advisor can help you understand the advantages and disadvantages of investment properties.
- 07/24/2023
|
Alcon (ALC) Gains From Robust Contact Lense Sales, Launches
- In Equipment, Alcon (ALC) continues to upgrade and expand its installed base with the CENTURION and LEGION devices.
- 07/18/2023
|
Alcon (ALC) Hits 52-Week High: What's Driving the Stock?
- Investors are bullish about Alcon (ALC) owing to solid demand, strong commercial execution and pricing improvements across the Surgical and Vision Care franchises.
- 07/12/2023
|
Alcon (ALC) Surgical End Market Grows, Vision Care Sales Rise
- In Equipment, Alcon (ALC) continues to upgrade and expand its installed base with the CENTURION and LEGION devices.
- 07/10/2023
|
Are Medical Stocks Lagging Alcon (ALC) This Year?
- Here is how Alcon (ALC) and Swedish Orphan Biovitrum (BIOVF) have performed compared to their sector so far this year.
- 06/15/2023
|
Here's Why You Should Retain Alcon (ALC) Stock for Now
- Investors continue to be optimistic about Alcon (ALC) on the impressive performance of the Surgical and Vision Care segments.
- 06/14/2023
|
Is Alcon (ALC) Stock Outpacing Its Medical Peers This Year?
- Here is how Alcon (ALC) and Swedish Orphan Biovitrum (BIOVF) have performed compared to their sector so far this year.
- 05/30/2023
|
Alcon (ALC) Vision Care Sales Robust, Margin Pressure Persists
- For Alcon (ALC), in terms of end market, Surgical global cataract procedure growth varies significantly by region.
- 05/17/2023
|
ALC or EW: Which Is the Better Value Stock Right Now?
- Investors interested in Medical - Instruments stocks are likely familiar with Alcon (ALC) and Edwards Lifesciences (EW). But which of these two stocks is more attractive to value investors?
- 04/28/2023
|
ALC vs. IDXX: Which Stock Is the Better Value Option?
- Investors interested in stocks from the Medical - Instruments sector have probably already heard of Alcon (ALC) and Idexx Laboratories (IDXX). But which of these two stocks offers value investors a better bang for their buck right now?
- 04/12/2023
|
What Makes Alcon (ALC) a New Buy Stock
- Alcon (ALC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 04/10/2023
|
ALC vs. ISRG: Which Stock Is the Better Value Option?
- ALC vs. ISRG: Which Stock Is the Better Value Option?
- 03/20/2023
|
Alcon (ALC) Unveils Expansive Vision Care Products at SECO 2023
- Alcon (ALC) showcases its reusable toric lens and dry eye/ocular health offerings at the SECO International Meeting 2023 in Atlanta.
- 03/06/2023
|
ALC vs. ISRG: Which Stock Should Value Investors Buy Now?
- ALC vs. ISRG: Which Stock Is the Better Value Option?
- 03/02/2023
|
Alcon Inc. (ALC) Q4 2022 Earnings Call Transcript
- Alcon Inc. (NYSE:ALC ) Q4 2022 Earnings Conference Call February 28, 2023 8:00 AM ET Company Participants Dan Cravens - Vice President & Global Head of Investor Relations David Endicott - Chief Executive Officer Tim Stonesifer - Chief Financial Officer Conference Call Participants Graham Doyle - UBS Anthony Petrone - Mizuho Group Larry Biegelsen - Wells Fargo Daniel Buchta - ZKB Matthew Mishan - Keybanc Capital Markets Veronika Dubajova - Citi Cecilia Furlong - Morgan Stanley Ryan Zimmerman - BTIG Chris Gretler - Credit Suisse Operator Greetings and welcome to the Alcon's Fourth Quarter and Full Year 2022 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded.
- 02/28/2023
|
Alcon: Case Of Growth Destructive To Value, Reiterate Hold At 24x Earnings
- A firm creates value when its return on invested capital exceeds its cost of capital. If it doesn't, regardless of its expansion, growth will become destructive to shareholder value.
- 02/01/2023
|
Alcon's (ALC) Latest Buyout to Enhance Its Product Portfolio
- Alcon's (ALC) ophthalmic pharmaceutical product suite is expected to be significantly boosted by adding new products following the recent acquisition.
- 11/24/2022
|
Alcon (ALC) Q3 Earnings Surpass Estimates, Sales Guidance Cut
- Alcon's (ALC) robust innovation pipeline is delivering solid results as evidenced by the strength in its comprehensive portfolio of PCIOLs, including PanOptix and Vivity.
- 11/23/2022
|
Alcon: Eyeing A Growth Story That Could Benefit From A Weaker Dollar
- It's rare to find a high-growth foreign company that isn't stuck in a big downtrend. While ALC shares are down sharply year-on-year, its valuation is not so bad considering impressive EPS growth.
- 11/18/2022
|
Alcon Inc. (ALC) Q3 2022 Earnings Call Transcript
- Alcon Inc. (NYSE:ALC ) Q3 2022 Earnings Conference Call November 16, 2022 8:00 AM ET Company Participants Dan Cravens - Vice President and Global Head, Investor Relations David Endicott - Chief Executive Officer Tim Stonesifer - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Julien Dormois - BNP Paribas Daniel Buchta - ZKB Larry Biegelsen - Wells Fargo Matthew Mishan - KeyBanc Capital Markets Jeff Johnson - Baird Cecilia Furlong - Morgan Stanley Joanne Wuensch - Citi Falko Friedrichs - Deutsche Bank Zach Weiner - Jeffries Operator Greetings. And welcome to the Alcon Third Quarter 2022 Earnings Call.
- 11/16/2022
|
Alcon (ALC) Faces Cost Pressure, Supply Chain Disruption
- Given the supply chain challenges, unfavorable foreign exchange impact and inflationary pressure, Alcon (ALC) reduces its core EPS and net sales expectations for 2022.
- 09/13/2022
|
Alcon: Looking To Break Downtrend Before Entry
- Alcon has continued in a downtrend since September 2021 with persistent mean reversion activity across this time. With FY22 guidance narrowed and macro-headwinds prevailing, forward-looking multiples are less attractive to peers.
- 09/04/2022
|
Don't Look for Alcon's Acquisition to Boost Share Price in Short Term
- Most investors would probably be pleased with a share price gain of 33% in just over three years, but more than 50% sounds a lot better.
- 08/24/2022
|
Aerie set to be bought by Alcon for $770 million
- New Jersey-based biotech firm Aerie is seeing its shares move higher amid news of it being bought by Aerie Pharmaceuticals.
- 08/23/2022
|
Blistering-Hot Biotech Shopping Spree Continues: Alcon To Buy Aerie For $770 Million
- Alcon will buy glaucoma drugs maker Aerie Pharmaceuticals in a $770 million deal that sent the biotech stock flying Tuesday. The post Blistering-Hot Biotech Shopping Spree Continues: Alcon To Buy Aerie For $770 Million appeared first on Investor's Business Daily.
- 08/23/2022
|
Alcon to Acquire Aerie Pharmaceuticals for $15.25 a Share
- Alcon agrees to acquire Aerie, the ophthalmic therapies company, for $15.25 a share.
- 08/23/2022
|
Alcon (ALC) Q2 Earnings Surpass Estimates, Guidance Lowered
- Alcon's (ALC) robust innovation pipeline is delivering solid results as evidenced by the successful launch of new ATIOL roles and SiHy contact lenses.
- 08/11/2022
|
Alcon Inc. (ALC) CEO David Endicott on Q2 2022 Results - Earnings Call Transcript
- Alcon Inc. (NYSE:ALC ) Q2 2022 Results Conference Call August 10, 2022 8:00 AM ET Company Participants Dan Cravens - VP and Global Head IR David Endicott - CEO Tim Stonesifer - CFO Conference Call Participants Zach Weiner - Jeffries Chris Cooley - Stephens Daniel Buchta - ZKB Larry Biegelsen - Wells Fargo Matthew Mishan - KeyBanc Capital Ryan Zimmerman - BTIG Cecilia Furlong - Morgan Stanley Jeff Johnson - Baird Julien Dormois - BNP Paribas David Adlington - JPMorgan Operator Greetings and welcome to the Second Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.
- 08/10/2022
|
Alcon's (ALC) Product Launches, Market Recovery Aid Growth
- Despite bearing the brunt of inflationary pressure across both Total Surgical and Vision Care franchises, Alcon (ALC) succeeds in mitigating much of the impact through cost-improvement efforts.
- 07/18/2022
|
Here's Why Alcon (ALC) is a Strong Momentum Stock
- The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
- 07/11/2022
|
Here's Why Investors Should Retain Alcon (ALC) Stock For Now
- Investors are optimistic about Alcon's (ALC) better-than-expected results and robust performance across its popular franchises.
- 06/09/2022
|
Alcon: Revisiting The Investment Thesis
- Alcon continues to grow at a double-digit rate and is on track to achieve management's full-year guidance. Both the Surgical and the Vision Care segments delivered double-digit growth, which highlights a solid demand for the company's products in every category.
- 06/03/2022
|
Alcon (ALC) Signs EYSUVIS-Buyout Deal With Kala Pharmaceuticals
- The acquisition of EYSUVIS complements Alcon's (ALC) Systane family of eye drops offering, strengthening its treatment options for dry eye disease.
- 05/23/2022
|
Alcon (ALC) Q1 Earnings Surpass Estimates, Margins Grow
- Alcon (ALC) delivers better-than-expected results in the first quarter, with strong performance across both franchises driving the top line.
- 05/12/2022
|
Alcon Inc. (ALC) CEO David Endicott on Q1 2022 Results - Earnings Call Transcript
- Alcon Inc. (NYSE:ALC ) Q1 2022 Results Conference Call May 11, 2022 8:00 AM ET Company Participants Dan Cravens - VP, IR David Endicott - CEO Tim Stonesifer - CFO Conference Call Participants Daniel Buchta - ZKB Larry Biegelsen - Wells Fargo Matthew Mishan - KeyBanc Capital Markets Matt Miksic - Credit Suisse Joanne Wuensch - Citi Cecilia Furlong - Morgan Stanley Zach Weiner - Jefferies Ryan Zimmerman - BTIG Graham Doyle - UBS Jeff Johnson - Baird David Adlington - JP Morgan Julien Dormois - BNP Paribas Operator Greetings and welcome to the Alcon First Quarter 2022 Earnings Conference. At this time, all participants are in a listen-only mode.
- 05/11/2022
|
3 Medical Product Stocks Set to Beat on Earnings This Season
- Medical product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how CGC, HAE and ALC are poised ahead of their earnings releases.
- 05/09/2022
|
3 Medical Product Stocks Poised to Beat This Earnings Season
- Medical product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how ALC, ZBH and CSII are poised ahead of their earnings releases.
- 04/25/2022
|
3 Medical Instruments Stocks to Buy Despite Industry Headwinds
- The Zacks Medical - Instruments industry is growing on R&D investments. ALC, STE and ABMD are set to gain the most.
- 04/19/2022
|
Alcon (ALC) Stock Rallies 4.7% Since Posting Q4 Earnings Beat
- Alcon (ALC) stock rallies on robust growth across all Surgical and Vision Care sales categories.
- 04/12/2022
|
Alcon's (ALC) Surgical Arm Rebounds, New Launches Aid Growth
- In Vision Care, Alcon (ALC) continues to see strong demand for PRECISION1 and PRECISION1 for Astigmatism, which are the company's newest contact lenses for the mainstream market.
- 04/11/2022
|
Alcon (ALC) Publishes Dividend, New Board Member Addition Plans
- Alcon's 2022 AGM is set to take place in a closed format without the personal presence of shareholders.
- 03/28/2022
|
Here's Why You Should Hold on to Alcon (ALC) Stock for Now
- Investors are optimistic about Alcon's (ALC) better-than-expected results and robust segmental performance.
- 03/21/2022
|
The Recent Pullback Makes Alcon More Attractive
- Since my previous article on ALC, the stock is down ~10% vs. ~6% for the S&P 500 and is now fairly valued in my opinion for a 6% return.
- 03/18/2022
|
Alcon (ALC) Expands in the U.S. With New Clareon IOLs Launch
- With the latest launch, Alcon's (ALC) Clarion Monofocal, Clareon PanOptix, Clareon PanOptix Toric, Clareon Vivity and Clareon Vivity Toric IOLs are now available in the United States.
- 03/08/2022
|
Alcon CEO sees positive momentum for product launches in 2022
- Alcon CEO David Endicott says he expects all geographies to return to pre-pandemic growth levels in 2022. He speaks with CNBC's Julianna Tatelbaum following the eyecare company's full-year 2021 earnings.
- 02/17/2022
|
Alcon Inc. (ALC) CEO David Endicott on Q4 2021 Results - Earning Call Transcript
- Alcon Inc. (ALC) CEO David Endicott on Q4 2021 Results - Earning Call Transcript
- 02/16/2022
|
BMEZ: Buy Low, Hold For The Distribution And Rebound
- BMEZ: Buy Low, Hold For The Distribution And Rebound
- 02/07/2022
|
Alcon's (ALC) Global Growth Solid, New Lenses Sales Rise
- Alcon's (ALC) new contact lenses are gaining market share and the Systane brand family has been posting strong double-digit growth in all regions.
- 01/19/2022
|
Alcon (ALC) Launches Preservative-Free Drops for Dry Eye Relief
- Alcon's (ALC) new preservative-free solution for patients with dry eye symptoms is the latest addition to its leading global artificial tear brand Systane.
- 01/14/2022
|
Alcon (ALC) Vision Care Sales Grow Despite Supply Disruption
- Alcon's (ALC) new contact lenses are gaining market share and the Systane brand family has been posting strong double-digit growth in all regions.
- 12/28/2021
|
Here's Why You Should Hold on to Alcon (ALC) Stock for Now
- Investors are optimistic about Alcon's (ALC) better-than-expected third-quarter results and robust performance by the Vision Care arm.
- 12/20/2021
|
Alcon (ALC) on Track With Successful Global PRECISION1 Rollout
- Alcon (ALC) enhances contact lens experience, especially for new wearers, with the continued successful rollout of PRECISION1.
- 12/16/2021
|
Alcon (ALC) Surgical Arm Grows Amid Global Trade Disruption
- Segment wise, within Alcon's (ALC) Surgical arm, the portfolio of advanced technology intraocular lenses is driving increased penetration rates of ATIOLs.
- 11/23/2021
|
Alcon (ALC) Q3 Earnings Beat Estimates, Margin Improves
- Alcon (ALC) records year-over-year growth across all sales categories in Surgical and Vision Care in Q3.
- 11/12/2021
|
Alcon Big Winner in 2019 Divorce From Novartis
- Since being spun off into a separate company in April 2019, Alcon Inc. ( ALC , Financial) shares have thrived while the stock of its former parent, Novartis AG ( NVS , Financial), has languished.
- 11/10/2021
|
Alcon Inc. (ALC) CEO David Endicott on Q3 2021 Results - Earning Call Transcript
- Alcon Inc. (ALC) CEO David Endicott on Q3 2021 Results - Earning Call Transcript
- 11/10/2021
|
Alcon's (ALC) Robust Product Line, Market Rebound Aid Growth
- In Presbyopia-correcting Intraocular Lens (PCIOLs), Alcon (ALC) currently leads the market with over 55% of global share and over 80% share in the United States.
- 10/04/2021
|
Alcon Honored with FutureEdge 50 Award
- FORT WORTH, Texas--(BUSINESS WIRE)--Alcon Honored with FutureEdge 50 Award
- 09/27/2021
|
Here's Why You Should Add Alcon Stock (ALC) to Your Portfolio
- Investors continue to be optimistic about Alcon (ALC) backed by robust second-quarter performance and raised 2021 outlook.
- 09/27/2021
|
Alcon Inc. (ALC) CEO David Endicott on Q2 2021 Results - Earnings Call Transcript
- Alcon Inc. (ALC) CEO David Endicott on Q2 2021 Results - Earnings Call Transcript
- 08/18/2021
|
Alcon (ALC) Q2 Earnings Top Estimates, 2021 Guidance Up
- Alcon (ALC) records the highest sales in the second quarter of 2021 since its spin-off.
- 08/18/2021
|
Alcon Shares Increase Over 10% Pre-Market: Why It Happened
- The shares of Alcon (NYSE: ALC) increased by over 10% pre-market. This is why it happened.
- 08/18/2021
|
Investors Cheer Alcon's Updated Annual Guidance
- Alcon AG (NYSE: ALC) reported second-quarter FY21 sales of $2.1 billion, +75% Y/Y on a reported basis and +69% on a constant currency basis, beating the consensus of $1.96 billion. All categories benefited from the improvements in the eye care market, led by the strong recovery in the U.S. and varied paces of recovery in international markets from the COVID-19 pandemic.
- 08/18/2021
|
Alcon Reports Second Quarter 2021 Results
- GENEVA--(BUSINESS WIRE)--Alcon Reports Second Quarter 2021 Results
- 08/17/2021
|
Alcon (ALC) to Report Q2 Earnings: What's in the Cards?
- Continued strength in the Surgical segment and new launches under Vision Care segment are likely to have driven growth in the second quarter for Alcon (ALC).
- 08/13/2021
|
Alcon to Launch TOTAL30 as the First-and-Only Monthly Replacement, Water Gradient Contact Lens
- GENEVA--(BUSINESS WIRE)--Alcon to Launch TOTAL30 as the First-and-Only Monthly Replacement, Water Gradient Contact Lens
- 08/11/2021
|
3 Medical Instruments Stocks Countering Industry Headwinds
- The Zacks Medical - Instruments industry is growing on base business recovery. ISRG, IDXX and ALC are set to gain the most.
- 08/04/2021
|
Alcon Reinforces Strength of Industry-Leading Ophthalmology Portfolio with Largest Surgical Device Scientific Presence at ASCRS 2021
- FORT WORTH, Texas--(BUSINESS WIRE)--Alcon Reinforces Strength of Industry-Leading Ophthalmology Portfolio with Largest Surgical Device Scientific Presence at ASCRS 2021
- 07/22/2021
|
Alcon Announces Executive Committee Changes
- GENEVA--(BUSINESS WIRE)--Alcon Announces Executive Committee Changes
- 06/28/2021
|
Alcon to Showcase Vision Care Innovation, Including Clinical Data for its Forthcoming Reusable Monthly Lens TOTAL30, at BCLA 2021
- GENEVA--(BUSINESS WIRE)--Alcon to Showcase Vision Care Innovation, Including Clinical Data for its Forthcoming Reusable Monthly Lens TOTAL30, at BCLA 2021
- 06/07/2021
|
Alcon Inc. (ALC) CEO David Endicott on Q1 2021 Results - Earnings Call Transcript
- Alcon Inc. (ALC) CEO David Endicott on Q1 2021 Results - Earnings Call Transcript
- 05/05/2021
|
Alcon to Acquire U.S. Commercialization Rights to Ophthalmic Eye Drop Simbrinza
- GENEVA--(BUSINESS WIRE)--Alcon to Acquire U.S. Commercialization Rights to Ophthalmic Eye Drop Simbrinza
- 04/28/2021
|
Alcon Launches Systane Hydration Multi-Dose Preservative-Free Lubricant Eye Drops in the U.S.
- GENEVA--(BUSINESS WIRE)--Alcon Launches Systane Hydration Multi-Dose Preservative-Free Lubricant Eye Drops in the U.S.
- 04/28/2021
|
Alcon: Updated Medium-Term Plan Highlights The Growth And Margin Opportunity
- Alcon holds an upbeat capital markets day event, outlining its updated medium-term targets into 2025. A rich product pipeline and upcoming expansion plans underpin the growth and margin outlook.
- 04/25/2021
|
Top Wall Street analysts bet on these stocks for long-term growth
- TipRanks analyst ranking service pinpoints Wall Street's best-performing stocks, like Alcon, Semtech, Upstart, and others.
- 03/28/2021
|
Where Alcon Stands With Analysts
- Alcon (NYSE:ALC) has observed the following analyst ratings within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 1 1 0 0 Somewhat Bullish 0 2 0 0 Indifferent 0 0 0 0 Somewhat Bearish 0 0 0 0 Bearish 0 0 0 0 5 analysts offering 12-month price targets in the last 3 months for Alcon evaluate the company at an average price target of $80.6 with a high of $86.00 and a low of $75.00.
- 03/25/2021
|
Alcon Publishes Agenda for Annual General Meeting
- GENEVA--(BUSINESS WIRE)--Alcon Publishes Agenda for Annual General Meeting
- 03/24/2021
|
Alcon to Host Virtual Capital Markets Day on March 24
- GENEVA--(BUSINESS WIRE)--Alcon to Host Virtual Capital Markets Day on March 24
- 03/12/2021
|
Alcon's Sue-Jean Lin Wins 2021 Dallas CIO of the Year
- FORT WORTH, Texas--(BUSINESS WIRE)--Alcon's Sue-Jean Lin Wins 2021 Dallas CIO of the Year
- 03/01/2021
|
Alcon, Inc. (ALC) CEO David Endicott on Q4 2020 Results - Earnings Call Transcript
- Alcon, Inc. (ALC) CEO David Endicott on Q4 2020 Results - Earnings Call Transcript
- 02/24/2021
|
Alcon, Inc. (ALC) Presents at JPMorgan Healthcare Conference - (Transcript)
- Alcon, Inc. (ALC) Presents at JPMorgan Healthcare Conference - (Transcript)
- 01/12/2021
|
Alcon: Global Leader In An Attractive End-Market
- Eye-care devices market is an attractive end-market supported by secular growth trends such as aging population, increased myopia prevalence, and innovation in products leading to better outcomes for patients. I believe Alcon will be able to grow above the market in the medium term, driven by near-term product flow and pipeline, increased focus, and entrenched leadership.
- 12/16/2020
|
Alcon, Inc. (ALC) CEO David Endicott on Q3 2020 Results - Earnings Call Transcript
- Alcon, Inc. (ALC) CEO David Endicott on Q3 2020 Results - Earnings Call Transcript
- 11/11/2020
|
Unable to provide full-year guidance due to difficult market conditions, Alcon CEO says
- Alcon CEO David Endicott discusses the company's third-quarter earnings.
- 11/11/2020
|
Alcon: Q3 Earnings Insights
- Shares of Alcon (NYSE:ALC) rose 2.73% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share decreased 15.22% year over year to $0.39, which beat the estimate of $0.22.
- 11/10/2020
|
Tracking George Soros's Portfolio - Q2 2020 Update
- Soros' 13F portfolio value increased from $1.98B to $4.48B this quarter. The number of positions increased from 118 to 141.
- 08/21/2020
|
Alcon Inc (ALC) Q2 2020 Earnings Call Transcript
- ALC earnings call for the period ending June 30, 2020.
- 08/19/2020
|
Alcon Inc. 2020 Q2 - Results - Earnings Call Presentation
- The following slide deck was published by Alcon Inc. in conjunction with their 2020 Q2 earnings call..
- 08/19/2020
|
Alcon Inc. (ALC) CEO David Endicott on Q2 2020 Results - Earnings Call Transcript
- Alcon Inc. (NYSE:ALC) Q2 2020 Results Conference Call August 19, 2020 08:00 AM ET Company Participants Karen King - SVP, Corporate Affairs David Endicott - CEO Tim Stonesifer - CFO Conference Call Participants Veronika Dubajova - Goldman Sachs Matt Miksic - Credit Suisse Jeff Johnson - Baird Steve Willoughby - Cleveland Research David Lewis - Morgan Stanley Anthony Petrone - Jefferies Matthew Mishan - KeyBanc Larry Biegelsen - Wells Fargo Chris Cooley - Stephens, Inc.
- 08/19/2020
|
Wall Street Breakfast: S&P 500 To Take Aim At New Record
- Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.
- 08/19/2020
|
Alcon second-quarter loss widens as it boosts COVID-19 provisions
- Alcon on Wednesday posted a wider second-quarter loss as the Swiss eyecare products maker increased provisions for expected COVID-19 related credit losses. The quarterly loss was $422 million, versus $390 million in the 2019 period, Alcon said.
- 08/19/2020
|
Alcon Reports Second Quarter 2020 Results
- Alcon Reports Second Quarter 2020 Results
- 08/18/2020
|
Alcon Reports Second Quarter 2020 Results
- Alcon Reports Second Quarter 2020 Results
- 08/18/2020
|
Not Your Father’s Tesla
- PREVIEW When it comes to electric-vehicle announcements, investors have gotten used to alluring and fast cars. (TSLA)’s top Model S sedan can go from zero to 60 miles per hour in 2.3 seconds. But the electric-vehicle revolution is going to come in all shapes, sizes, and speeds.
- 08/15/2020
|
Tracking Tweedy Browne Portfolio - Q2 2020 Update
- Tweedy Browne’s 13F portfolio value increased from $2.15B to $2.51B this quarter. The largest five individual stock positions are Alphabet, Berkshire Hathaway, Johnson & Johnson, Cisco Systems, and Baidu, and they account for ~55% of the portfolio.
- 08/12/2020
|
Acutus Medical Files For IPO For Commercialization Push
- Acutus Medical has filed to raise $75 million in a U.S. IPO, although the final figure may differ.
- 07/23/2020
|
Harding Loevner Global Equity Fund Q2 2020 Letter
- Harding Loevner is an investment manager that invests primarily in publicly traded global equities. We were founded in 1989 by former managers for the Rockefeller family.
- 07/22/2020
|
Alcon Survey Shows More Screen Time Causing Consumer Concern About Eye Health, Increasing Symptoms of Dry Eye
- Alcon Survey Shows More Screen Time Causing Consumer Concern About Eye Health, Increasing Symptoms of Dry Eye
- 07/21/2020
|
Did Hedge Funds Make The Right Call On Alcon Inc. (ALC) ?
- At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each stock might be going. […]
- 07/20/2020
|
Alcon to Showcase Latest Innovations, Data at American Society of Retina Specialists 2020 Virtual Annual Meeting
- Alcon to Showcase Latest Innovations, Data at American Society of Retina Specialists 2020 Virtual Annual Meeting
- 07/17/2020
|
Alcon Issues First Corporate Responsibility Report as Independent Company
- Alcon Issues First Corporate Responsibility Report as Independent Company
- 07/15/2020
|
Wedgewood Partners Q2 2020 Client Letter
- Wedgewood Partners is a money manager founded in 1988 with the goal of providing investors with a superior approach to managing investment portfolios.
- 07/14/2020
|
Why Alcon (ALC) is an Incredible Growth Stock?
- On July 14, 2020, Wedgewood Partners released its Q2 2020 Investor Letter, a copy of which you can download here. The Fund returned 27.13% for the second quarter of 2020. Meanwhile, the benchmark Russell 1000 Growth Index and the Russell 1000 Value Index gained 27.84% and 14.29%, respectively. You should check out Wedgewood Partners' top […]
- 07/14/2020
|
Alcon Announces FDA Approval of the OTC Switch of Pataday Once Daily Relief Extra Strength
- Alcon Announces FDA Approval of the OTC Switch of Pataday Once Daily Relief Extra Strength
- 07/14/2020
|
Benzinga's Top Upgrades, Downgrades For July 6, 2020
- Upgrades * Monness Crespi Hardt upgraded the stock for CyberArk Software Ltd (NASDAQ: CYBR) from Neutral to Buy. CyberArk Software earned $0.50 in the first quarter, compared to $0.56 in the year-ago quarter. The stock has a 52-week-high of $148.74 and a 52-week-low of $69.50. CyberArk Software's stock last closed at $102.97 per share. * Citigroup upgraded the stock for Tandem Diabetes Care Inc (NASDAQ: TNDM) from Neutral to Buy. For the first quarter, Tandem Diabetes Care had an EPS of ($0.25), compared to year-ago quarter EPS of ($0.18). The stock has a 52-week-high of $103.95 and a 52-week-low of $43.69. Tandem Diabetes Care's stock last closed at $98.58 per share. * Evercore ISI Group changed the rating for US Silica Holdings Inc (NYSE: SLCA) from Underperform to In-Line. For the first quarter, US Silica Holdings had an EPS of ($0.03), compared to year-ago quarter EPS of ($0.08). The stock has a 52-week-high of $14.83 and a 52-week-low of $0.79. US Silica Holdings's stock last closed at $3.35 per share. * For Coca-Cola European Partners PLC (NYSE: CCEP), ABN Amro upgraded the stock from Hold to Buy. The stock has a 52-week-high of $58.94 and a 52-week-low of $28.35. Coca-Cola European's stock last closed at $38.08 per share. * For Marcus Corp (NYSE: MCS), B. Riley FBR upgraded the stock from Neutral to Buy. For the first quarter, Marcus had an EPS of ($0.29), compared to year-ago quarter EPS of $0.13. The stock has a 52-week-high of $37.64 and a 52-week-low of $6.95. Marcus's stock last closed at $13.22 per share. Downgrades * Cowen & Co. downgraded the stock for Flowserve Corp (NYSE: FLS) from Outperform to Market Perform. In the first quarter, Flowserve showed an EPS of $0.21, compared to $0.41 from the year-ago quarter. The stock has a 52-week-high of $53.82 and a 52-week-low of $18.98. Flowserve's stock last closed at $28.31 per share. * Benchmark downgraded the stock for Healthcare Services Group Inc (NASDAQ: HCSG) from Buy to Hold. For the first quarter, Healthcare Services Group had an EPS of $0.27, compared to year-ago quarter EPS of $0.12. The stock has a 52-week-high of $31.84 and a 52-week-low of $15.80. Healthcare Services Group's stock last closed at $24.30 per share. * Imperial Capital downgraded the stock for Netflix Inc (NASDAQ: NFLX) from Outperform to In-Line. Netflix earned $1.57 in the first quarter, compared to $0.76 in the year-ago quarter. The stock has a 52-week-high of $492.28 and a 52-week-low of $252.28. Netflix's stock last closed at $476.89 per share. * Goldman Sachs changed the rating for Intel Corp (NASDAQ: INTC) from Neutral to Sell. Intel earned $1.45 in the first quarter, compared to $0.89 in the year-ago quarter. The stock has a 52-week-high of $69.29 and a 52-week-low of $43.63. Intel's stock last closed at $59.13 per share. * Bernstein downgraded the stock for Spotify Technology SA (NYSE: SPOT) from Market Perform to Underperform. In the first quarter, Spotify Technology showed an EPS of ($0.22), compared to ($0.90) from the year-ago quarter. The stock has a 52-week-high of $274.30 and a 52-week-low of $109.18. Spotify Technology's stock last closed at $271.49 per share. * KeyBanc downgraded the stock for Evolent Health Inc (NYSE: EVH) from Overweight to Sector Weight. In the first quarter, Evolent Health showed an EPS of ($0.14), compared to ($0.31) from the year-ago quarter. The stock has a 52-week-high of $12.01 and a 52-week-low of $3.50. Evolent Health's stock last closed at $7.40 per share. * Baird downgraded the stock for The Cooper Companies Inc (NYSE: COO) from Outperform to Neutral. For the second quarter, Cooper Companies had an EPS of $1.51, compared to year-ago quarter EPS of $2.94. The stock has a 52-week-high of $365.68 and a 52-week-low of $236.68. Cooper Companies's stock last closed at $289.95 per share. * Piper Sandler changed the rating for Globus Medical Inc (NYSE: GMED) from Overweight to Neutral. For the first quarter, Globus Medical had an EPS of $0.29, compared to year-ago quarter EPS of $0.36. The stock has a 52-week-high of $60.15 and a 52-week-low of $33.41. Globus Medical's stock last closed at $49.17 per share. Initiations * Citigroup initiated coverage on Thor Industries Inc (NYSE: THO) with a Neutral rating. For the third quarter, Thor Industries had an EPS of $0.43, compared to year-ago quarter EPS of $1.65. The stock has a 52-week-high of $118.89 and a 52-week-low of $32.30. Thor Industries's stock last closed at $106.42 per share. * For Winnebago Industries Inc (NYSE: WGO), Citigroup initiated coverage, by setting the current rating at Neutral. In the third quarter, Winnebago Industries showed an EPS of ($0.26), compared to $1.14 from the year-ago quarter. The stock has a 52-week-high of $72.65 and a 52-week-low of $16.94. Winnebago Industries's stock last closed at $65.96 per share. * BTIG initiated coverage on Venus Concept Inc (NASDAQ: VERO) with a Buy rating. The price target for Venus Concept is set at $7.00. Venus Concept earned ($1.68) in the first quarter. The stock has a 52-week-high of $9.00 and a 52-week-low of $2.06. Venus Concept's stock last closed at $3.52 per share. * For Translate Bio Inc (NASDAQ: TBIO), William Blair initiated coverage, by setting the current rating at Outperform. Translate Bio earned ($0.24) in the first quarter, compared to ($0.74) in the year-ago quarter. The stock has a 52-week-high of $28.09 and a 52-week-low of $6.80. Translate Bio's stock last closed at $17.86 per share. * Goldman Sachs initiated coverage on Carvana Co (NYSE: CVNA) with a Neutral rating. The price target for Carvana is set at $108.00. In the first quarter, Carvana showed an EPS of ($1.18), compared to ($0.53) from the year-ago quarter. The stock has a 52-week-high of $132.55 and a 52-week-low of $22.16. Carvana's stock last closed at $128.61 per share. * RBC Capital initiated coverage on Okta Inc (NASDAQ: OKTA) with an Outperform rating. The price target for Okta is set at $230.00. For the first quarter, Okta had an EPS of ($0.07), compared to year-ago quarter EPS of ($0.19). The stock has a 52-week-high of $212.01 and a 52-week-low of $88.66. Okta's stock last closed at $207.76 per share. * B. Riley FBR initiated coverage on SRAX Inc (NASDAQ: SRAX) with a Buy rating. The price target for SRAX is set at $4.00. For the fourth quarter, SRAX had an EPS of ($0.40), compared to year-ago quarter EPS of ($0.94). The stock has a 52-week-high of $5.63 and a 52-week-low of $1.05. SRAX's stock last closed at $2.48 per share. * Goldman Sachs initiated coverage on Vroom Inc (NASDAQ: VRM) with a Neutral rating. The price target for Vroom is set at $46.00. The stock has a 52-week-high of $59.00 and a 52-week-low of $38.46. Vroom's stock last closed at $54.30 per share. * RBC Capital initiated coverage on Zscaler Inc (NASDAQ: ZS) with an Outperform rating. The price target for Zscaler is set at $130.00. In the third quarter, Zscaler showed an EPS of $0.07, compared to $0.05 from the year-ago quarter. The stock has a 52-week-high of $115.17 and a 52-week-low of $35.00. Zscaler's stock last closed at $110.21 per share. * KeyBanc initiated coverage on Alcon Inc (NYSE: ALC) with a Sector Weight rating. For the first quarter, Alcon had an EPS of $0.45, compared to year-ago quarter EPS of $0.39. The stock has a 52-week-high of $65.37 and a 52-week-low of $39.37. Alcon's stock last closed at $58.75 per share. * Citigroup initiated coverage on Harley-Davidson Inc (NYSE: HOG) with a Buy rating. The price target for Harley-Davidson is set at $33.00. For the first quarter, Harley-Davidson had an EPS of $0.51, compared to year-ago quarter EPS of $0.98. The stock has a 52-week-high of $40.89 and a 52-week-low of $14.31. Harley-Davidson's stock last closed at $23.42 per share. * With a rating of Outperform, Baird initiated coverage on Vroom Inc (NASDAQ: VRM). The price target is set at $68.00 for Vroom. The stock has a 52-week-high of $59.00 and a 52-week-low of $38.46. Vroom's stock last closed at $54.30 per share.See more from Benzinga * 18 Healthcare Stocks Moving In Monday's Pre-Market Session * 4 Consumer Defensive Stocks Moving In Monday's Pre-Market Session * 13 Technology Stocks Moving In Monday's Pre-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 07/06/2020
|
Hedge Funds Aren’t Done Buying Alcon Inc. (ALC)
- The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of March 31st, 2020. […]
- 06/15/2020
|
New Strong Sell Stocks for June 2nd
- Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today
- 06/02/2020
|
Alcon Prices US$750.0 Million Senior Notes Offering
- Alcon prices US$750.0 million senior notes offering
- 05/18/2020
|
Alcon Inc (ALC) Q1 2020 Earnings Call Transcript
- Joining me on today's call are David Endicott, our Chief Executive Officer; and Tim Stonesifer, our Chief Financial Officer. Accordingly, you should not place undue reliance on any forward-looking statements.
- 05/13/2020
|
Dow Jones Falls Over 500 Points on Wednesday
- Alcon jumps on the back of strong first-quarter results Continue reading...
- 05/13/2020
|
Alcon Reports First Quarter 2020 Results
- Alcon Reports First Quarter 2020 Results
- 05/12/2020
|
Alcon to Highlight Robust Scientific Program Showcasing Latest Innovations at Virtual American Society of Cataract and Refractive Surgery 2020 Annual Meeting
- Alcon to Highlight Robust Scientific Program Showcasing Latest Innovations at Virtual ASCRS 2020
- 05/11/2020
|
Alcon Shareholders Approve All Proposed Resolutions at the 2020 Annual General Meeting
- Alcon shareholders approve all proposed resolutions at the 2020 Annual General Meeting
- 05/06/2020
|
BVI Names David Murray as Chief Financial Officer
- BVI, a leading developer, manufacturer, and marketer of surgical devices for the ophthalmic marketplace, announced today that it has named David Murray as Chief Financial Officer. Most recently, David served as Chief Financial Officer of Alcon AG from 2015 until its $30bn spin-off from Novartis Group
- 04/28/2020
|
Novartis maintains strong operational performance in Q1, confirms FY 2020 guidance at this time, and advances a broad range of efforts to support the global response to COVID-19
- Q1 2020 net sales from continuing operations1 grew 13% (cc2, +11% USD) with double digit growth (cc) in Innovative Medicines and Sandoz: Key growth drivers include.
- 04/28/2020
|
Surgical ophthalmology market to garner phenomenal gains over 2020-2025
- Selbyville, Delaware, April 27, 2020 -- The global surgical ophthalmology market recorded a remuneration of USD 10,625.74 million in 2019 and is estimated to accrue substantial.
- 04/27/2020
|
Global Artificial Tears Industry
- Artificial Tears market worldwide is projected to grow by US$457.1 Million, driven by a compounded growth of 3.7%. Artificial Tears, one of the segments analyzed and sized in this study, displays the potential to grow at over 3.7%. The shifting dynamics supporting this growth makes it critical for businesses
- 04/22/2020
|
BTIG Maintains a Hold Rating on Alcon (ALC)
- In a report released today, Ryan Zimmerman from BTIG maintained a Hold rating on Alcon (ALC). The company's shares closed last Friday at $53.13. According
- 04/20/2020
|
BTIG Maintains a Hold Rating on Alcon (ALC)
- In a report released today,
Ryan Zimmerman
from BTIG maintained a
Hold
rating on Alcon (
ALC
–
Research Report
). The company’s shares closed last Friday at $53.13.
According to
TipRanks.com
, Zimmerman is a 5-star analyst with an average return of
1
- 04/20/2020
|
Analysts Offer Insights on Healthcare Companies: Tecan Group AG (OtherTCHBF) and Alcon (ALC)
- Analysts have been eager to weigh in on the Healthcare sector with new ratings on Tecan Group AG (TCHBF) and Alcon (ALC). Tecan Group AG (TCHBF) Kepler
- 04/20/2020
|
Analysts Offer Insights on Healthcare Companies: Tecan Group AG (Other OTC: TCHBF) and Alcon (NYSE: ALC)
- Analysts have been eager to weigh in on the Healthcare sector with new ratings on Tecan Group AG (
TCHBF
–
Research Report
) and Alcon (
ALC
–
Research Report
).
Tecan Group AG (TCHBF)
Kepler Capital
analyst
Maja Pataki
maintained a
Hold
rating on Te
- 04/20/2020
|
10 of the Best Blue-Chip Stocks to Buy for 2019
- The best blue-chip stocks for 2020. When investors think of blue-chip stocks, they think of tried and true, large companies with entrenched businesses. They think of robust cash flows, healthy financials ...
- 04/17/2020
|
Analysis of COVID-19-Global Glaucoma Surgery Devices Market 2020-2024 | Evolving Opportunities with Alcon Inc. and Allergan Plc | Technavio
- The glaucoma surgery devices market size has the potential to grow by USD 1.53 billion during 2020-2024
- 04/15/2020
|
The Global Tissue Ablation Market is expected to grow from USD 13,823.13 Million in 2018 to USD 22,452.13 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 7.17%
- The Global Tissue Ablation Market is expected to grow from USD 13,823.13 Million in 2018 to USD 22,452.13 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 7.17%. Read the full report: https://www.reportlinker.com/p05871683/?utm_source=PRN The positioning of the Global Tissue Ablation
- 04/15/2020
|
Glaucoma Surgery Devices Market Size Worth $2.6 Billion by 2027: Grand View Research, Inc.
- The global glaucoma surgery devices market size is estimated to reach USD 2.6 billion by 2027, registering a CAGR of 6.9%, according to a new report by Grand View Research, Inc. Growing geriatric population and high treatment cost of medications are some of the major factors driving the market. High
- 04/13/2020
|
3 Hidden Gem Healthcare Stocks
- Three stocks worth watching.
- 04/10/2020
|
Alcon price target lowered to $58 from $70 at Wells Fargo ALC
- Alcon price target lowered to $58 from $70 at Wells Fargo Wells Fargo ALC
- 04/09/2020
|
Tango Therapeutics Raises $60 Million Series B Financing and Strengthens Executive Team
- Tango Therapeutics raises $60 million Series B financing round and announces three leadership appointments.
- 04/09/2020
|
Ophthalmic Drugs Market Size, Share & Trends Analysis Report By Drug Class, By Disease, By Dosage Form, By Route Of Administration, By Product Type, By Region And Segment Forecasts, 2020 - 2027
- New York, April 08, 2020 -- Reportlinker.com announces the release of the report "Ophthalmic Drugs Market Size, Share & Trends Analysis Report By Drug Class, By Disease, By.
- 04/08/2020
|
Alcon (ALC) Receives a Rating Update from a Top Analyst
- In a report released today, Richard Newitter from Leerink Partners maintained a Hold rating on Alcon (ALC), with a price target of $56.00. The company's
- 04/08/2020
|
Macy’s, Kraft Heinz rise; Alcon, NXP Semiconductor fall
- Stocks that moved heavily or traded substantially on Tuesday: Macy’s, Kraft Heinz rise; Alcon, NXP Semiconductor fall
- 04/07/2020
|
Macy’s, Kraft Heinz rise; Alcon, NXP Semiconductor fall
- NEW YORK (AP) — Stocks that moved heavily or traded substantially on Tuesday: Exxon Mobil Corp., up 77 cents to $41.24 The energy giant its slashing its spending plans due to weak demand and a market flooded with an oversupply...
- 04/07/2020
|
Macy's, Kraft Heinz rise; Alcon, NXP Semiconductor fall
- The maker of eye care products withrew its financial forecasts for this year and will delay a decision on paying a dividend until next year. The chipmaker said the impact from COVID-19 on its first-quarter results would be worse than it had forecast on March 2.
- 04/07/2020
|
The Daily Biotech Pulse: Sanofi, Regeneron Finalize Praluent Restructuring, Natus Pre-Announces Q1 Shortfall, Alcon To Delay Dividend Initiation
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs April 6.) * Forty Seven Inc (NASDAQ: FTSV) * Masimo Corporation (NASDAQ: MASI) * Seattle Genetics, Inc. (NASDAQ: SGEN) * Vertex Pharmaceuticals Incorporated
- 04/07/2020
|
Alcon Provides Update on COVID-19
- Alcon provides update on COVID-19
- 04/07/2020
|
Is Royal Caribbean Cruises Ltd. (RCL) A Good Stock To Buy?
- Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]
- 04/06/2020
|
Here is What Hedge Funds Think About Southwest Airlines Co. (LUV)
- Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]
- 04/06/2020
|
Here is What Hedge Funds Think About AutoZone, Inc. (AZO)
- Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]
- 04/06/2020
|
Workiva Hosts its Largest Event To Date
- Workiva (NYSE:WK), provider of the world’s leading connected reporting and compliance platform, today announced that nearly 2,400 customers, partners and industry leaders attended its recent, two-day virtual event to discuss streamlining processes and consolidating data in the Workiva platform’s secure
- 03/30/2020
|
Hedge Funds Have Never Been This Bullish On Cintas Corporation (CTAS)
- We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
- 03/29/2020
|
Hedge Funds Have Never Been More Bullish On Alcon Inc. (ALC)
- Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]
- 03/29/2020
|
Top Analyst Upgrades and Downgrades: Alibaba, Apple, AT&T, Baidu, Chevron, Cisco, Expedia, Goldman Sachs, Kroger, Micron, Nike, P&G, Square, Walmart and More
|
Tracking David Rolfe's Wedgewood Partners Portfolio - Q4 2019 Update
- Wedgewood Partners’ 13F portfolio decreased from $1.13B to $987M this quarter. David Rolfe added S&P Global and increased Nvidia, while dropping Ulta Beauty. Th
- 03/26/2020
|
Qiagen (QGEN) Receives a Hold from Kepler Capital
- In a report released yesterday, Maja Pataki from Kepler Capital maintained a Hold rating on Qiagen (QGEN), with a price target of EUR39.00. The company's
- 03/25/2020
|
Qiagen (QGEN) Receives a Hold from Kepler Capital
- In a report released yesterday,
Maja Pataki
from Kepler Capital
maintained a
Hold
rating on Qiagen (
QGEN
–
Research Report
), with a price target of
EUR39.00
. The company’s shares closed last Monday at $39.86.
According to
TipRanks.com
, Pataki is
- 03/25/2020
|
Siemens Healthineers AG (SEMHF) Gets a Hold Rating from Kepler Capital
- Kepler Capital analyst Maja Pataki maintained a Hold rating on Siemens Healthineers AG (SEMHF) yesterday and set a price target of EUR43.50. The company's
- 03/25/2020
|
Siemens Healthineers AG (SEMHF) Gets a Hold Rating from Kepler Capital
- Kepler Capital
analyst
Maja Pataki
maintained a
Hold
rating on Siemens Healthineers AG (
SEMHF
–
Research Report
) yesterday and set a price target of
EUR43.50
. The company’s shares closed last Monday at $39.18.
According to
TipRanks.com
, Pataki is
- 03/25/2020
|
Kepler Capital Maintains Their Hold Rating on Tecan Group AG (TCHBF)
- Kepler Capital analyst Maja Pataki maintained a Hold rating on Tecan Group AG (TCHBF) yesterday and set a price target of CHF276.00. The company's shares
- 03/25/2020
|
Kepler Capital Maintains Their Hold Rating on Tecan Group AG (TCHBF)
- Kepler Capital
analyst
Maja Pataki
maintained a
Hold
rating on Tecan Group AG (
TCHBF
–
Research Report
) yesterday and set a price target of
CHF276.00
. The company’s shares closed last Monday at $253.00.
According to
TipRanks.com
, Pataki is a 1-st
- 03/25/2020
|
Alcon upgraded to Hold from Sell at Societe Generale ALC
- Alcon upgraded to Hold from Sell at Societe Generale Societe Generale ALC
- 03/24/2020
|
Alcon (ALC) Gets a Hold Rating from Stephens
- Stephens analyst Chris Cooley maintained a Hold rating on Alcon (ALC) today and set a price target of $50.00. The company's shares closed last Monday at
- 03/23/2020
|
Alcon (ALC) Gets a Hold Rating from Stephens
- Stephens analyst
Chris Cooley
maintained a
Hold
rating on Alcon (
ALC
–
Research Report
) today and set a price target of
$50.00
. The company’s shares closed last Monday at $40.70, close to its 52-week low of $39.37.
According to
TipRanks.com
, Cool
- 03/23/2020
|
Edited Transcript of GKOS earnings conference call or presentation 27-Feb-20 9:30pm GMT
- Q4 2019 Glaukos Corp Earnings Call
- 03/23/2020
|
We Give Spun-Off Alcon a $38 Fair Value Estimate; Turnaround Optics Are Good, but Stock Overpriced
|
Benzinga's Top Upgrades, Downgrades For March 13, 2020
- Upgrades * Northland upgraded the stock for Advanced Micro Devices Inc (NASDAQ: AMD) from Market Perform to Outperform. For the fourth quarter, Advanced Micro Devices had an EPS of $0.32, compared to year-ago quarter EPS of $0.08. The stock has a 52-week-high of $59.27 and a 52-week-low of $22.78.
- 03/13/2020
|
Tracking Tweedy Browne Portfolio - Q4 2019 Update
- Tweedy Browne's 13F portfolio value decreased marginally from $2.83B to $2.77B this quarter. The largest five individual stock positions are Berkshire Hathaway,
- 03/13/2020
|
The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) * Masimo Corporation (NASDAQ: MASI)Down In The Dumps (Biotech stocks that hit 52-week lows March 12.) * Abbott Laboratories (NYSE: ABT) * ABIOMED
- 03/13/2020
|
Ophthalmology Diagnostics Market: Growth, Trends, and Forecasts to 2025 - Key Players are Ziemer Ophthalmic Systems, Topcon Corporation, Carl Zeiss, Metall Zug, and Alcon
- Dublin, March 13, 2020 -- The "Ophthalmology Diagnostics Market - Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's.
- 03/13/2020
|
Alcon Announces European Launch of Vivity, the Only Presbyopia-correcting Intraocular Lens With X-WAVE Technology
- Alcon announces European launch of Vivity, the only presbyopia-correcting intraocular lens with X-WAVE technology
- 03/12/2020
|
Alcon Partners with Actress Cheryl Ladd to Share Her Cataract Journey, Renewed Vision and PanOptimist Story
- Alcon Partners with Actress Cheryl Ladd to Share Her Cataract Journey, Renewed Vision and PanOptimist Story
- 03/11/2020
|
Global Ophthalmic Diagnostic Devices Market Expected to Grow at a CAGR of 6% Over the Period, 2020-2024 - ResearchAndMarkets.com
- The "Global Ophthalmic Diagnostic Devices Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.
- 03/10/2020
|
Global Surgical Ophthalmology Market: Analysis, Insight, Competition & Forecast During the Period, 2020-2025 - ResearchAndMarkets.com
- The "Global Surgical Ophthalmology Market - Analysis By Surgery Type, Product, End User, By Region, By Country (2020 Edition): Market Insight, Competition and Forecast (2020-2025)" report has been added to ResearchAndMarkets.com's offering.
- 03/09/2020
|
Ocular Implants Market to Reach USD 7.94 Billion by 2026; Increasing Investment in Product R&D to Aid Growth, says Fortune Business Insights™
- Pune, March 09, 2020 -- The global ocular implants market size is projected to reach USD 7.94 billion by 2026. Technological advancements have played a key role towards the.
- 03/09/2020
|
Edited Transcript of STAA earnings conference call or presentation 26-Feb-20 9:30pm GMT
- Q4 2019 STAAR Surgical Co Earnings Call
- 03/09/2020
|
Global Surgical Ophthalmology Market - Analysis By Surgery Type, Product, End User, Region and Country: Market Insight, Competition and Forecast (2020-2025)
- The "Global Surgical Ophthalmology Market - Analysis By Surgery Type, Product, End User, By Region, By Country (2020 Edition): Market Insight, Competition and Forecast (2020-2025)" report has been added to ResearchAndMarkets.com's offering.
- 03/06/2020
|
Edited Transcript of COO earnings conference call or presentation 5-Mar-20 10:00pm GMT
- Q1 2020 Cooper Companies Inc Earnings Call
- 03/06/2020
|
New sell-side coverage - healthcare
- 10X Genomics (NASDAQ:TXG) initiated with Buy rating and $95 (23% upside) price target at Guggenheim.Abbott (NYSE:ABT) initiated with Buy rating at Citigroup. Shares down 1% premarket.Alcon (NYSE:ALC)
- 03/05/2020
|
Global Ophthalmic Diagnostic Devices Market 2020-2024 | Evolving Opportunities With Alcon Inc. and AMETEK Inc. | Technavio
- The global ophthalmic diagnostic devices market will grow by USD 980 million during 2020-2024
- 03/04/2020
|
The Global Ophthalmic Diagnostic Devices MARKET is expected to grow by USD 0.98 bn during 2020-2024, progressing at a CAGR of 6% during the forecast period
- New York, March 03, 2020 -- Reportlinker.com announces the release of the report "Global Ophthalmic Diagnostic Devices Market 2020-2024" -.
- 03/04/2020
|
Global Intraocular Lenses Industry
- New York, March 03, 2020 -- Reportlinker.com announces the release of the report "Global Intraocular Lenses Industry" - https://www.reportlinker.com/p05205331/?utm_source=GNW.
- 03/03/2020
|
Global Intraocular Lenses Industry
- Intraocular Lenses market worldwide is projected to grow by US$1.8 Billion, driven by a compounded growth of 5.5%. Standard, one of the segments analyzed and sized in this study, displays the potential to grow at over 1.5%. The shifting dynamics supporting this growth makes it critical for businesses
- 03/03/2020
|
Insights into the Global Surgical Ophthalmology Market to 2025 - Companies Analysed Include Hoya Corporation, Bausch Health and Johnson & Johnson
- Dublin, March 03, 2020 -- The "Global Surgical Ophthalmology Market - Analysis By Surgery Type, Product, End User, By Region, By Country (2020 Edition): Market Insight,.
- 03/03/2020
|
Global Surgical Ophthalmology Market – Analysis By Surgery Type, Product, End User, By Region, By Country : Market Insight, Competition and Forecast
- New York, March 02, 2020 -- Reportlinker.com announces the release of the report "Global Surgical Ophthalmology Market – Analysis By Surgery Type, Product, End User, By Region,.
- 03/03/2020
|
Global Ophthalmology Diagnostics Market Trends Report, 2020-2025
- The "Ophthalmology Diagnostics Market - Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.
- 03/02/2020
|
LivaNova (LIVN) Gets a Buy Rating from Berenberg Bank
- Berenberg Bank analyst Scott Bardo maintained a Buy rating on LivaNova (LIVN) yesterday and set a price target of $114.00. The company's shares closed
- 02/27/2020
|
LivaNova (LIVN) Gets a Buy Rating from Berenberg Bank
- Berenberg Bank analyst
Scott Bardo
maintained a
Buy
rating on LivaNova (
LIVN
–
Research Report
) yesterday and set a price target of
$114.00
. The company’s shares closed last Monday at $62.70, close to its 52-week low of $62.48.
According to
TipRan
- 02/27/2020
|
TJX, Alcon rise; Dycom, Toll Brothers fall
- Stocks that moved heavily or traded substantially on Wednesday: TJX, Alcon rise; Dycom, Toll Brothers fall
- 02/26/2020
|
TJX, Alcon rise; Dycom, Toll Brothers fall
- NEW YORK (AP) — Stocks that moved heavily or traded substantially on Wednesday: Dycom Industries Inc., down $12.46 to $30.26. The construction and engineering company reported an unexpectedly big fourth-quarter loss. National Vision Holdings Inc., up $4.77 to $38.60. The...
- 02/26/2020
|
BYND, ALC among premarket gainers
- SELLAS Life Sciences Group (NASDAQ:SLS) +23% on positive follow-up phase 1/2 clinical data for Galinpepimut-S in acute myeloid leukemia.Alcon (NYSE:ALC) +10% on Q4 results.Moderna (NASDAQ:MRNA) +9% on
- 02/26/2020
|
Tracking George Soros' Portfolio - Q4 2019 Update
- Soros' 13F portfolio value decreased from $3.61B to $3.09B this quarter. The number of positions decreased from 175 to 173. Soros increased NortonLifeLock, Arch
- 02/21/2020
|
Workiva aiuta Alcon ad adattare la revisione globale, la gestione del rischio delle imprese e la compliance SOX
- Workiva (NYSE:WK), fornitore della prima piattaforma connessa di revisione e compliance al mondo, oggi ha annunciato che Alcon (NYSE:ALC) sta utilizza
- 02/11/2020
|
Workiva apporte son aide Alcon afin d’optimiser son audit mondial, la gestion des risques d'entreprise et la conformit SOX
- Workiva (NYSE:WK), plateforme numéro un pour le reporting connecté et la conformité, a annoncé aujourd'hui qu’Alcon (NYSE:ALC) utilise la plateforme W
- 02/11/2020
|
Samenvatting: Workiva helpt Alcon, Enterprise Risk Management en SOX naleving om wereldwijde audit op te schalen
- Workiva (NYSE: WK), leverancier van ‘s werelds toonaangevende verbonden rapportage- en complianceplatform, heeft vandaag aangekondigd dat Alcon (NYSE:
- 02/11/2020
|
Workiva untersttzt Alcon bei der Skalierung von Rechnungslegung, Unternehmensrisikomanagement und Einhaltung der SOX-Vorgaben auf weltweiter Ebene
- Workiva (NYSE:WK), Anbieter der weltweit führenden vernetzten Berichts- und Compliance-Plattform, gab heute bekannt, dass Alcon (NYSE:ALC) die Workiva
- 02/11/2020
|
Workiva Helps Alcon Scale Global Audit, Enterprise Risk Management and SOX Compliance
- Workiva (NYSE:WK), provider of the world’s leading connected reporting and compliance platform, today announced that Alcon (NYSE:ALC) is using the Workiva platform to build and scale its global audit, Enterprise Risk Management (ERM) and Sarbanes Oxley Act (SOX) compliance processes.
- 02/11/2020
|
Publicis Groupe: 2019 Annual Results
- 2019 Full Year Results - Solid results in a transformation year February 6, 2020 Reported net revenue up 9.3% for the full year, with Epsilon contributing in.
- 02/06/2020
|
Publicis Groupe: 2019 Full Year Results
- 2019 Full Year Results
- 02/06/2020
|
Ophthalmic Surgical Devices Market to Hit $12.75 Bn by 2026; Increasing Popularity of LASIK Surgical Procedure to Boost Market Growth: Fortune Business Insights™
- Pune, Feb. 04, 2020 -- The global Ophthalmic Surgical Devices Market size is anticipated to reach USD 12.75 billion by 2026, registering a CAGR of 4.8% during the forecast.
- 02/04/2020
|
Novartis (NVS) Earnings and Revenues Miss Estimates in Q4
- Novartis (NVS) reports disappointing results for the fourth quarter but provides an encouraging outlook for 2020.
- 01/29/2020
|
The Daily Biotech Pulse: Novartis Earnings, Hepion's NASH Candidate Beats Rival Drugs, Annovis Bio To Debut
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 28) 10X Genomics Inc (NASDAQ: TXG ) Acceleron Pharma Inc ...
- 01/29/2020
|
Novartis delivered strong sales growth, margin expansion and breakthrough innovation launching five NMEs in 2019
- Full year net sales for continuing operations1 up 9% (cc2, +6% USD): Pharmaceuticals BU growing 12% (cc) driven by Cosentyx USD 3.6 billion (+28% cc), Entresto USD 1.7 billion.
- 01/29/2020
|
Tracking Kahn Brothers Portfolio - Q4 2019 Update
- Kahn Brothers Group's 13F portfolio value increased from $798M to $825M this quarter. Sterling Bancorp position was reduced substantially during the quarter. Th
- 01/28/2020
|
Ocugen Stock Might be up 34% in 2020 but There are Other Eye Care Plays
- Except for a couple of specific investors, Ocugen stock is not one for average people. Instead, look at Bausch Health Companies, which has a very rocky backstory but has managed to turn the corner.
- 01/21/2020
|
Cataract Surgical Devices Market to Reach USD 9.98 Billion by 2026; Presence of Favorable Reimbursement Policies to Aid Growth, says Fortune Business Insights™
- Pune, Jan. 20, 2020 -- The global Cataract Surgical Devices Market size is projected to reach USD 9.98 billion by the end of 2026. The high prevalence of cataract disorders.
- 01/20/2020
|
Cataract Surgical Devices Market to Reach USD 9.98 Billion by 2026; Presence of Favorable Reimbursement Policies to Aid Growth, says Fortune Business Insights™
- Key Companies Covered in the Cataract Surgical Devices Market Research Report are Alcon (Part of Novartis AG), Johnson and Johnson Services, Inc., ZEISS International, Bausch & Lomb Incorporated, STAAR SURGICAL, Hoya Corporation, Oertli Instrumente AG, Rayner Intraocular Lenses Limited, Oculentis, SIFI S.p.A and other key market players.
- 01/20/2020
|
A Real Dividend Growth Machine: 2019 Portfolio Review
- Annual review of results from a real dividend growth stock portfolio. Discussion of portfolio changes in the second half of 2019. Example of how a dividend grow
- 01/16/2020
|
The Zacks Analyst Blog Highlights: Novartis, McDonald's, Bristol-Myers Squibb, CME and UBS
- The Zacks Analyst Blog Highlights: Novartis, McDonald's, Bristol-Myers Squibb, CME and UBS
- 01/10/2020
|
Top Analyst Reports for Novartis, McDonald's & Bristol-Myers Squibb
- Today's Research Daily features new research reports on 16 major stocks, including Novartis (NVS), McDonald's (MCD) and Bristol-Myers Squibb (BMY).
- 01/09/2020
|
3 Low Price-Book Stocks for Value Investors to Consider
- Bank of America tops the list Continue reading...
- 12/08/2019
|
Hedge Funds Have Never Been This Bullish On Alcon Inc. (ALC)
- Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]
- 12/07/2019
|
Hedge Funds Love Electronic Arts (EA) Way More Than These Stocks
- We are still in an overall bull market and many stocks that smart money investors were piling into surged through November 22nd. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 52% and 49% respectively. Hedge funds' top 3 stock picks returned 39.1% this year and beat the S&P; […]
- 11/30/2019
|
Top 5 Buys of George Soros' Firm in 3rd Quarter
- Firm of Hungarian-born guru releases portfolio Continue reading...
- 11/21/2019
|
David Rolfe Adds 2 Tech Stocks to Portfolio in 3rd Quarter
- Guru invests in Nvidia, CDW Continue reading...
- 11/18/2019
|
Invesco European Growth Fund Starts 1 Position, Boosts 5 Others in 3rd Quarter
- Fund releases quarterly portfolio as UK and European Union leaders negotiate Brexit deal Continue reading...
- 10/17/2019
|
Here is What Hedge Funds Think About Alcon Inc. (ALC)
- World-class money managers like Ken Griffin and Barry Rosenstein only invest their wealthy clients' money after undertaking a rigorous examination of any potential stock. They are particularly successful in this regard when it comes to small-cap stocks, which their peerless research gives them a big information advantage on when it comes to judging their worth. […]
- 10/10/2019
|
The Daily Biotech Pulse: Acceleron Shelves Muscular Dystrophy Drug Trial, Aclaris Aces Late-Stage Study
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 16) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alder ...
- 09/17/2019
|
The Daily Biotech Pulse: Nuvectra Explores Strategic Options, J&J To Contend Opioid Ruling, Sesen Bio Gets New CFO
- Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 26) DURECT Corporation (NASDAQ: DRRX ) Stoke Therapeutics ...
- 08/27/2019
|